Conde Nast Portfolio shines a light on Questcor

Writing for Conde Nast’s Portfolio.com (Drug Money), Russ Mitchell tells the story of Questcor’s almost 20-fold boost in the price of H.P. Achtar Gel, a treatment for infantile spasms. The article does a nice job recounting the story behind this move and the impact it’s having on physicians and patients. I’ve written a fair bit on this topic (see, for example Abusing the Orphan Drug law to rip off customers) and other bloggers have posted more in-depth pieces. Unfortunately until now the few pieces in the mainstream media have botched the story. The New York Times, for its part, decided to blame the price increase on PBMs like Express Scripts, which is a complete joke. (See New York Times is 7+ months late with H.P. Acthar Gel story and still misses the point.)
Thanks, Russ for getting it right.

July 22, 2008

One thought on “Conde Nast Portfolio shines a light on Questcor”

  1. Hi David,
    Somehow I missed this post last week and didn’t find Russ’ piece until after the JEC hearing last week.

    Here’s what I was busy doing instead.

    http://brassandivory.blogspot.com/2008/07/small-patient-population-big-drug.html

    http://brassandivory.blogspot.com/2008/07/price-gouging-in-extremely-vulnerable.html

    I can’t help but to think that Russ used the following series of posts (pre-JEC) as research for his articles. Some of the choice of language is too similar. But the important part is that a more correct characterization has now reached mainstream media.

Leave a Reply

Your email address will not be published. Required fields are marked *